Resistance to lung cancer targeted therapy can be reversed, study suggests

Up to 40 percent of lung cancer patients do not respond to a targeted therapy designed to block tumor growth — a puzzling clinical setback that researchers have long tried to solve. Now, scientists at Georgetown Lombardi Comprehensive Cancer Center and the National Cancer Institute have discovered why that intrinsic resistance occurs — and they pinpoint a drug they say could potentially reverse it. Read more here.